10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“practice guidelines increasingly recognize the prevention of ischemic events as a key management priority.5,6”
In the citing paper
“However, subsequent trials that specifically examined the role of a blood pressure lowering strategy to <130 mm Hg in patients with T2DM and hypertension found no substantive benefit of intensive blood pressure control in reducing the risk of coronary events, although there was evidence for decreased risk of stroke.5,66–69”
In the citing paper
“As such, while all patients with T2DM and CAD certainly benefit from a blood pressure of <140/90 mm Hg,5,63–66,76”
In the citing paper
“ACE inhibitors/ARBs reduce the progression of kidney disease in patients with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g)5 and reduce the risk of both incident and recurrent atherosclerotic ischemic events.79,80”
In the citing paper
“Furthermore, fibrates or fish oil would be indicated when triglycerides are very high (>500 mg/dL) to reduce the risk of pancreatitis.5”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Research works printed but not linked: 2
- American College of Obstetricians and Gynecologists’, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
- Fitchett, 2017, Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial, Eur Heart J, 39, 363, 10.1093/eurheartj/ehx511 · DOI · Paper page
Cited by
Items 401–470 of 470
Канорский, С. Г. (2020) · Kardiologiia · doi:10.18087/cardio.2020.2.n943
An Overview of the ACC/AHA Recommendations on Cholesterol Management in People With Diabetes
Bucheit, J. D., & Kelly, M. S. (2020) · ADCES in Practice · doi:10.1177/2633559x20902856
PURL: Aspirin, Yes, for at-risk elderly-but what about the healthy elderly?
Piggott, C., & Lyon, C. (2020) · PubMed
Sheikh, O., Nashawi, M., Battisha, A., & CHILTON, R. J. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000192 · Cited by 1
“Diabetes Care 2019; 42:S103–S123.”
Patel, P. M., & Vaidya, V. (2020) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12373
Mesa 1: Diabetes mellitus tipo 1 y enfermedad cardiovascular
González, L., Chertkoff, A., Burgos, M. A., Trifone, L., Sanabria, H. D., Koleff, C. K., Roccatagliata, L. E., Rama, V., Pomares, M. L., Suppo, M., et al. (2020) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v54i2sup.251 · Cited by 1
Pacientes com diabetes mellitus tipo 2 em uso de medicamentos via judicial
Ferreira, G. C., Mendonça, T. S., da Silva, E. S., Pereira, M. L., Belo, V. S., Ferreira, V. C., & Baldoni, A. O. (2020) · Revista Brasileira de Medicina de Família e Comunidade · doi:10.5712/rbmfc15(42)2561
Samigullin, A., Hammes, H., Siegel, E. G., Helms, T. M., Remppis, B. A., Humpert, P. M., & Morcos, M. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1306-7998
Shehab-Eldin, W. A., Al-ashmawy, A., Kamel, M., Elhelbawy, N., Dawood, A. A., & Elnajjar, M. M. (2020) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1174
Improving the quality of blood pressure measurements in an outpatient diabetes clinic
Iyengar, J. J., Johnson, M., Khairi, S., Fennelly, J. E., & Wyckoff, J. (2021) · BMJ Open Quality · doi:10.1136/bmjoq-2020-000917 · Cited by 1
Prevention of Cardiovascular Disease
Sharma, G. V., Minhas, A., & Michos, E. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819369-3.00013-7
Yang, E., Yoo, H., Jang, I., Yu, K., & Lee, S. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s288986
Maurantonio, M., Gabrielli, F., Castellano, C., Andrea, C., Andreoné, P., & Roncucci, L. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00035 · Cited by 1
Liu, M., Zhang, S., Chen, X. N., Guo, Y., Zhong, X., Xiong, Z., Lin, Y., Zhou, H., Huang, Y., Zhang, Z., et al. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0134
“In addition, three guidelines with similar recommendations [9-11] advocated that different official BP targets were appropriate for DM patients with/without CVD or with different CVD risks (official BP targets <130/80 mm Hg in DM patients with high CVD risk or CVD; official BP targets <140/85–90 mm…”
InfluentialGilyarevskiy, S. R. (2021) · Kardiologiia · doi:10.18087/cardio.2021.4.n1549 · Cited by 2
Optimizing Noncardiac Prescription in a Cardiac Patient
Sahib, A. K., & Chenniappan, M. (2020) · Bengal Physician Journal · doi:10.5005/jp-journals-10070-7032
Welche Ziel(wert)e sind relevant?
Jacob, S. (2020) · Info Diabetologie · doi:10.1007/s15034-020-2184-0
Arkhypkina, T. L., Lyubimovа, L. P., & Zaitseva, L. I. (2010) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2010.2.06
10-YEAR RISK ESTIMATION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN HYPERTENSIVE PATIENTS
Chernatska, O. M., & Sibongumusa, X. (2021) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2021;9(2):145-150
Bando, H., Kato, Y., Kato, Y., Yamashita, H., Yada, S., & OGURA, K. (2021) · Diabetes Research - Open Journal · doi:10.17140/droj-7-150
Efficacy of dulaglutide: an evidence-based review of its potential indications
Biryukova, E. V., & Solovyeva, I. V. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-7-18-30
Alipova, G., Bazarova, A., Bazarova, N., Bazarbekovna, B. R., Бедельбаева, Г. Г., Guseva, I. E., Junusbekova, G., Kassimbekovna, D. A., Jussupova, G., Mukarov, M., et al. (2021) · Journal Medicine · doi:10.31082/1728-452x-2021-223-1-2-14
Should my older adult patients take aspirin for primary prevention of cardiovascular disease?
Zimbroff, R. M., Ayers, G. T., & Koncilja, K. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.21024
Nutritional Aspects of Gestation and Puerperium
Saunders, C., & dos Santos, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-83434-0_8
Tsytovskyi, M. N., Logash, M. V., Савка, І. І., & Dmytriv, G. M. (2021) · Morphologia · doi:10.26641/1997-9665.2021.3.167-174
Lucchi, T. A. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch31
Reis, R. M. D. F., da Silva, D. A., Tavares, M. D. G., Nascimento, G. C., Damianse, S. D. S. P., Rocha, V. C. D. C., de Almeida, A. G. F. P., Lago, D. C. F., Rodrigues, V. P., Magalhães, M., et al. (2022) · Genes · doi:10.3390/genes13020389
Musiienko, V., & Марущак, М. І. (2022) · Medical and Clinical Chemistry · doi:10.11603/mcch.2410-681x.2021.i4.12651
Pratiti, R., Sud, P., Yousef, M., & Moza, A. (2022) · Frontiers in cardiovascular drug discovery · doi:10.2174/9789815036909122060003
Asmar, N. E., Arafah, B. M., & Smith, C. K. (2020) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_186-1
López‐Candales, A., & Norgard, N. B. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2082716
Triglyceride-Rich Lipoproteins
Bazarbashi, N., & Miller, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_12
Kalashnikov, V. Y., & Michurova, M. S. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.10.201911
Lu, Z. Q., McCourt, E. M., Goodhew, K., Gupta, D., Chuan, F., Mok, L., Peters, R., Ha, T., Fowler, D. H., Dobbyn, D., et al. (2022) · Internal Medicine Journal · doi:10.1111/imj.15993
Icosapent Ethyl for the Prevention of Cardiovascular Events
Lloyd, J. (2019) · EMJ Cardiology · doi:10.33590/emjcardiol/10311840
ผลการชะลอการเสื่อมของไตในผู้ป่วยไทยโรคเบาหวานชนิดที่ 2 ด้วยยา Empagliflozin
แผ่วัฒนากุล, เ. (2022) · Ramathibodi Medical Journal · doi:10.33165/rmj.2022.45.4.258675
Office/Out-of-Office Blood Pressure Measurements
Verdecchia, P., Reboldi, G., & Angeli, F. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_5
Beyond The Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy
González-Clemente, J. M., García, M. L., Gorgojo, J. J., Jiménez, A., Llorente, I., Matute, E., Pérez, C. T., Izarra, A., & Lecube, A. (2022) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/9/1/001155
Tukeni, K. N., Mohammed, E. U., Regassa, N. A., & Abera, E. G. (2023) · medRxiv · doi:10.1101/2023.02.13.23285845
Managing Stable Coronary Artery Disease in Diabetes
Koulouridis, I., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_23
Assessment of Cardiovascular Risk Factors Among Sudanese Patients with Type 2 Diabetes
Abdelrahim, H. M., Madani, A. M., & El-Hadiyah, T. M. (2023) · Sudan Journal of Medical Sciences · doi:10.18502/sjms.v18i2.13605
Moumen, A., Zraidi, M., Derrou, S., Benabdelfedil, Y., & Guendouz, F. E. (2023) · Clinical Diabetology · doi:10.5603/dk.a2023.0021
Ojeka, S. O., Zabbey, V. Z., & Edward, R. (2023) · Archives of Current Research International · doi:10.9734/acri/2023/v23i7595
Cardiovascular risk in older adults at the Policlínico "5 de Septiembre"
Álvarez, D. A. P., Vitón-Castillo, A. A., Marto, I. B., Díaz-Pita, G. F., & Esquivel, A. M. D. (2023) · Salud Ciencia y Tecnología · doi:10.56294/saludcyt2024685
Qammar, N., Zain, M., Jabeen, R., Deeba, F., Iqbal, N., Javeed, H. M. R., Alatawi, F. S., Alatawi, M. S., Almowallad, S. J., Alharbi, A. A., et al. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.2.4
“Cardiovascular disorders account for a significant portion of diabetes-related mortality and morbidity, and they also cost the country $37.3 billion annually in cardiovascular-related expenses [18].”
BackgroundInfluentialOkechukwu, U. C., Abonyi, M. C., & Eze, C. C. (2023) · Nigerian Journal of Medicine · doi:10.4103/njm.njm_103_23
¿Por qué debo bajar de peso si tengo diabetes o hipertensión?
González-Ortiz, J. A., González-Alvarado, F., & Pérez-Aguilar, A. D. J. (2024) · Atención Familiar · doi:10.22201/fm.14058871p.2024.388842
Марущак, М. І., Bandas, I., Заєць, Т. А., Prokopchuk, V. Y., & Krynytska, І. (2022) · Azerbajdžanskij medicinskij žurnal · doi:10.34921/amj.2022.4.017
Babatunde, O. T., Bewaji, C. O., & Igunnu, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4818392/v1
Naoum, I., Saliba, W. I., Barnett‐Griness, O., Aker, A., & Zafrir, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185541 · Cited by 3
“These findings emphasize the need to improve medical care in patients with T2D following ACS.”
BackgroundSGLT2 Inhibitors and Mechanism of Cardiovascular Benefits in Type 2 Diabetes
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_2 · Cited by 1
Jowi, S. O., Otieno, F. C. F., & Ogola, E. N. (2024) · British journal of healthcare and medical research · doi:10.14738/bjhmr.115.17745
Siahkouhian, M., Fasihi, L., & Ebrahimi-Torkamani, B. (2024) · Studies in Medical Sciences · doi:10.61186/umj.35.8.621
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
Chuntratip, N., Borvornsudhasin, P., & Tippinit, S. (2025) · Clinical Critical Care · doi:10.54205/ccc.v33.273733
Tian, J.-Q., Lin, Y., Zhang, Z.-J., Peng, Y.-T., Ye, J., & Wang, Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1637035
“Based on these data, the ADA has recommended GLP-1 RA and SGLT2i as fi rst-line agents for patients with T2DM and ASCVD after metformin since 2019 (39).”
Meiring, S., Busch, C. B. E., van Baar, A. C. G., Hemke, R., Holleman, F., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2022) · Figshare · doi:10.6084/m9.figshare.21191998
Fu, L., Zhou, Y., Sun, J., Zhu, Z., Xing, Z., Zhou, S., Wang, Y., & Tai, S. (2021) · Figshare · doi:10.6084/m9.figshare.16746808
Yang, Y., 彭年春, Chen, G., Wan, Q., Yan, L., Wang, G., Qin, Y., Luo, Z., Tang, X., Huo, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19029174
Olomu, A. B., Kelly‐Blake, K., Hart-Davidson, W., Gardiner, J., Luo, Z., Michele, H., & Holmes-Rovner, M. M. (2022) · Figshare · doi:10.6084/m9.figshare.20495980
Kim, H.-L., Kim, H. M., Kwon, C. H., Shin, J., Jung, M.-H., Lee, C. J., Kim, D.-H., Kim, W.-H., Kang, S.-H., Lee, J.-H., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13115009
Wu, H., Lau, E. S. H., Yang, A., Ronald, C. W., Kong, A. P. S., Chow, E., So, W.-Y., Chan, J. C. N., & Luk, A. O. Y. (2020) · Figshare · doi:10.6084/m9.figshare.12291593
Association Rule Mining for Combinatorial Biomarker Discovery. A Case Study on Type 2 Diabetes
Ciuciu, I. G., Ciobanu, D. M., Murg, D., & Lazar, C. (2026) · Communications in computer and information science · doi:10.1007/978-3-032-12481-4_17
Effect of Antithrombotic Therapy on Coronary Heart Disease Risk in People With Diabetes Mellitus
O’Donoghue, M., & Bhatt, D. L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00020-3
Endocan level and its association with glycemic and inflammatory indices in diabetic nephropathy
Al-Mayahi, L. M., & Shammaree, S. A. W. A. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02274-2
“This situation leads to increased morbidity, mortality, and significant healthcare costs for patients [3].”
Diabetes and Cardiovascular Diseases and Evolving Digital Health Technologies
Islam, S. M. S., Wahiduzzaman, M., Habib, A., Rahman, S., Karmakar, C. K., Banik, P. C., Faruque, M., Tegegne, T., Moses, J. C., & Azam, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_23
Role of Incretin Glucagon like Peptide 1 in Hypoglycemia
Dahiya, K., Dhankhar, K., & Dhankhar, R. (2026) · Indian Journal of Medical Biochemistry · doi:10.5005/jp-journals-10054-0355
Koyra, H. C., Anjulo, M. D., & Bekele, M. L. (2026) · Monaldi Archives for Chest Disease · doi:10.21203/rs.3.rs-11086304/v1
Nsengiyumva, P., Iracyahari, E., Sebera, E., Bitunguhali, L., Sebatunzi, O., Urengejeho, D., Masaisa, F., Woldeyes, E., & Tuyizere, A. (2026) · Research Square · doi:10.21203/rs.3.rs-10997646/v1
BindingDB Entry 50015357: Targeting Small GTPases and Their Prenylation in Diabetes Mellitus.
BindingDB (2024) · UC San Diego · doi:10.7270/q2t43z8r
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S103-S123
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4213222556
- Semantic Scholar
- b0a37d21ada65be89484f4b750bf45f281a7f7c5
- Cited by
- 471
- References
- 172
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 20 · 2023: 35 · 2022: 65 · 2021: 84 · 2020: 134 · 2019: 109
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care, treatment goals, level of evidence
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Humans, Risk Management, Societies, Medical, United States, Practice Guidelines as Topic, Diabetic Cardiomyopathies, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.